您的当前位置：首页 >光算蜘蛛池 >2023年營業收入約22.35億元 正文

2023年營業收入約22.35億元

时间：2025-06-16 23:00:59 来源：网络整理编辑：光算蜘蛛池

核心提示

收盤價：18.92元）4月19日晚間發布年度業績報告稱，2023年營業收入約22.35億元，同比減少2.88%；歸屬於上市公司股東的淨利潤虧損約3378萬元；基本每股收益虧損0.34元。博力威市光算蜘

收盤價：18.92元）4月19日晚間發布年度業績報告稱 ，2023年營業收入約22.35億元，同比減少2.88%；歸屬於上市公司股東的淨利潤虧損約3378萬元；基本每股收益虧損0.34元。博力威市光算谷歌seorong>光算蜘蛛池值為19億元。博力威的營業收入構成為：電氣機械和器材製造業占比94.92%。
2023年1至12月份，博力威（SH 68834光算谷歌seo5，光算蜘蛛池
截至發稿，（文章來源：每日經濟新聞）
上一篇：隔夜外盤：美股小幅收跌 熱門中概股多數下跌 百度跌超8%
下一篇：三六零：2023年淨虧損4.92億元 同比減虧 擬10派1元

推荐

热门

友情链接
光算谷歌营销光算爬虫池光算谷歌推广光算蜘蛛池光算谷歌营销光算谷歌营销光算谷歌营销光算爬虫池光算谷歌推广光算谷歌seo公司光算谷歌外鏈https://synapse.patsnap.com/drug/25727ac4a473471bb3b3db58523b65b4https://synapse.patsnap.com/article/what-are-dp1-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/article/biotech-advances-boost-oncology-market-to-5645b-amid-youth-cancer-increasehttps://synapse.patsnap.com/drug/a8865934bf39410a8b0ae8e0d6018981https://synapse.patsnap.com/drug/576d6709df774e7687f426dd26d8a452https://synapse.patsnap.com/article/how-many-fda-approved-genetically-engineered-subunit-vaccine-are-therehttps://synapse.patsnap.com/drug/88ae6a26537b490495042cf30f31ad88https://synapse.patsnap.com/article/what-are-ccl23-modulators-and-how-do-they-workhttps://synapse.patsnap.com/article/nurix-therapeutics-nx-5948-gains-fda-fast-track-for-waldenstrom%25E2%2580%2599s-macroglobumia-treatmenthttps://synapse.patsnap.com/article/what-are-smad-proteins-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/article/what-is-ergocalciferol-used-forhttps://synapse.patsnap.com/article/verona-preps-650m-for-copd-launch-ahead-of-fda-decisionhttps://synapse.patsnap.com/drug/8c78940999074aef860d3c59a6e41e8bhttps://synapse.patsnap.com/article/gan-lees-gzr18-gzr4-and-gzr101-injections-meet-phase-2-primary-endpointshttps://synapse.patsnap.com/drug/dedfe9645c0c41cea1b57efbbaa1a854https://synapse.patsnap.com/article/what-are-gss-stimulants-and-how-do-they-workhttps://synapse.patsnap.com/blog/a-comprehensive-review-of-hydrocortisone-sodium-succinates-randd-innovationshttps://synapse.patsnap.com/article/marea-releases-early-phase-2-data-for-novartis-licensed-cholesterol-drughttps://synapse.patsnap.com/drug/e1938479668e4ae7a463b399db2841a1https://synapse.patsnap.com/article/ars-pharmaceuticals-submits-snda-to-fda-for-neffy%25C2%25AE-1-mg-dose-for-children-15-30-kg-with-type-i-allergieshttps://synapse.patsnap.com/article/what-is-mirvetuximab-soravtansine-used-forhttps://synapse.patsnap.com/article/us-government-denies-bluebird-fertility-support-for-zynteglo-patientshttps://synapse.patsnap.com/drug/ee95ea45d73b4fcea8286efd24e72d2fhttps://synapse.patsnap.com/drug/6828622dfc8f4a01851e61c51dacb840https://synapse.patsnap.com/article/fda-lifts-partial-hold-on-rz358-for-congenital-hyperinsulinism-approves-us-inclusion-in-phase-3-studyhttps://synapse.patsnap.com/drug/f4eefd1a1849423e93e2fe676970b9b9https://synapse.patsnap.com/blog/bristol-myers-squibb-invests-in-cancer-immunotherapy-targeting-gpr65https://synapse.patsnap.com/drug/85b955c239e64ef88cd7cfeaacb14c76https://synapse.patsnap.com/article/fda-approves-amgen-drug-for-resistant-lung-cancerhttps://synapse.patsnap.com/article/prokidney-to-join-morgan-stanley-22nd-annual-global-healthcare-conference

免责声明：本站所有信息均来源于互联网搜集，并不代表本站观点，本站不对其真实合法性负责。如有信息侵犯了您的权益，请告知，本站将立刻删除。

Copyright © 2019 Powered by 2023年營業收入約22.35億元,煙台seo優化排名價格  

sitemap